Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07860554 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT07860554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07860554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 2, 2026
Completion date
December 31, 2028
Enrollment
88 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate adenocarcinoma, stage ivb prostate cancer ajcc v8